首页> 外文期刊>Circulation. Heart failure >Insights Into Myocardial Oxygen Consumption, Energetics, and Efficiency Under Left Ventricular Assist Device Support Using Noninvasive Pressure-Volume Loops
【24h】

Insights Into Myocardial Oxygen Consumption, Energetics, and Efficiency Under Left Ventricular Assist Device Support Using Noninvasive Pressure-Volume Loops

机译:使用非侵入压力量环留下左心室辅助装置支持的心肌氧气消耗,能量和效率的见解

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Assessment of left ventricular (LV) recovery under continuous-flow LV assist device therapy is hampered by concomitant pump support. We describe derivation of noninvasive pressure-volume loops in continuous-flow LV assist device patients and demonstrate an application in the assessment of recovery. Methods and Results: Using pump controller parameters and noninvasive arterial pressure waveforms, central aortic pressure, outflow conduit pressure gradient, and instantaneous LV pressure were calculated. Instantaneous LV volumes were calculated from echocardiographic LV end-diastolic volume accounting for the integral of pump flow with respect to time and aortic ejection volume derived from the pump speed waveform. Pressure-volume loops were derived during pump speed adjustment and following bolus intravenous milrinone to assess changes in loading conditions and contractility, respectively. Fourteen patients were studied. Baseline noninvasive LV end-diastolic pressure correlated with invasive pulmonary arterial wedge pressure (r(2)=0.57, root mean square error 5.0 mm Hg, P=0.003). Measured noninvasively, milrinone significantly increased LV ejection fraction (40.3 +/- 13.6% versus 36.8 +/- 14.2%, P<0.0001), maximum dP/dt (623 +/- 126 versus 555 +/- 122 mm Hg/s, P=0.006), and end-systolic elastance (1.03 +/- 0.57 versus 0.89 +/- 0.38 mm Hg/mL, P=0.008), consistent with its expected inotropic effect. Milrinone reduced myocardial oxygen consumption (0.15 +/- 0.06 versus 0.16 +/- 0.07 mL/beat, P=0.003) and improved myocardial efficiency (43.7 +/- 14.0% versus 41.2 +/- 15.5%, P=0.001). Reduced pump speed caused increased LV end-diastolic volume (190 +/- 80 versus 165 +/- 71 mL, P<0.0001) and LV end-diastolic pressure (14.3 +/- 10.2 versus 9.9 +/- 9.3 mm Hg, P=0.024), consistent with a predictable increase in preload. There was increased myocardial oxygen consumption (0.16 +/- 0.07 versus 0.14 +/- 0.06 mL O-2/beat, P<0.0001) despite unchanged stroke work (P=0.24), reflecting decreased myocardial efficiency (39.2 +/- 12.7% versus 45.2 +/- 17.0%, P=0.003). Conclusions: Pressure-volume loops are able to be derived noninvasively in patients with the HeartWare HVAD and can detect induced changes in load and contractility.
机译:背景技术:通过伴随的泵支撑,在连续流动LV辅助装置治疗下对左心室(LV)回收的评估受到阻碍。我们描述了连续流动LV辅助装置患者中非侵入性压力量环的推导,并在评估恢复时证明了应用。方法和结果:使用泵控制器参数和非侵入动脉压力波形,计算中央主动脉压力,流出导管压梯度和瞬时LV压力。从超声心动图LV端 - 舒张分体积计算瞬时LV体积,占泵流相对于泵速波形的时间和主动脉喷射体积的整体。在泵速调节期间和推注静脉内MilrinOne的压力体积环分别评估负载条件和收缩性的变化。研究了十四名患者。基线非侵入性LV端舒张压与侵入性肺动脉楔压相关(R(2)= 0.57,根均方误差5.0mm Hg,p = 0.003)。无侵略性地测量,MilRinOne显着增加LV喷射部分(40.3 +/- 13.6%,与36.8 +/-14.2%,P <0.0001),最大DP / DT(623 +/- 126对555 +/- 122 mm Hg / s, P = 0.006),末端收缩弹性(1.03 +/- 0.57对0.89 +/- 0.38 mm Hg / ml,p = 0.008),其符合其预期的官能效果。 Milrinone降低了心肌氧消耗(0.15 +/- 0.06对0.16 +/- 0.07 ml /拍打,P = 0.003),并且改善心肌效率(43.7 +/-14.0%,与41.2 +/- 15.5%,p = 0.001)。降低泵速引起的LV端舒张型体积增加(190 +/- 80对165 +/- 71mL,P <0.0001)和LV端舒张压(14.3 +/- 10.2与9.9 +/- 9.3 mm Hg,p = 0.024),与预载荷的可预测增加一致。尽管中风工作不变(P = 0.24),但反射心肌效率降低(316 +/- 0.06 o-0.1.0.06,P <0.0001,P <0.0001)的心肌氧消耗量增加与45.2 +/- 17.0%,p = 0.003)。结论:压力体积循环能够在心脏HVAD患者中非侵入地衍生,并且可以检测诱导负荷和收缩性的变化。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号